In Australia, Collagen Solutions PLC, which is registered in London and has global headquarters in Minnesota, received additional patent protection. The patent allows Collagen to source animal-based biomaterials from Australia for their pericardium tissue for heart valve replacements, orthopedics, dental industry, wound healing, surgery, and other medical uses. Australia and New Zealand are often sought-after by companies looking for high quality animal-based biomaterials because they have strict controls and have been doing it for a long time. Collagen’s CEO, Jamal Rushdy, told Proactive Investors UK, “This recent patent further strengthens our position in sourcing tissue in Australia in a novel way. We believe the additional processing covered in this patent will be of significant interest to our existing customer base.”